FTRE (Fortrea Holdings Inc) Bathi resik

The visual price representation available on GURU.Markets correlates with the effectiveness of Fortrea Holdings Inc. (FTRE) personnel policies regarding expert retention through global career growth. Profit stands at -0.07, while the business relies on an increase in late-stage trial orders and fresh B2B deals. The company's stability is based on the volume of research outsourcing by industry behemoths, despite restructuring costs.

FTRE (Fortrea Holdings Inc) riwayat Penghasilan resik saka 21.02.2024 nganti 01.11.2026

Rincian analitis lan laporan data perusahaan Fortrea (FTRE)

- rega lan prakiraan konsensus rega:

Kutipan saham Fortrea Clinical|FTRE - Prakiraan konsensus analis

- indikator valuasi pasar bisnis:

Kapitalisasi pasar Fortrea Clinical|FTRE - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data kapitalisasi buku:

Nilai Akuntansi Saham Fortrea|FTRE - Aset Bersih Perusahaan|Multiplikator Kapitalisasi Pasar marang Nilai Buku fortrea.com|FTRE - Total Aset Perusahaan

- informasi babagan utang lan solvabilitas:

- indikator pendapatan resik lan kelipatan nilai:

FTRE - Bathi resik perusahaan

Ringkesan analisis perusahaan:Fortrea Clinical - FTRE

Fortrea Holdings Inc. (FTRE) maintains its status as a reputable clinical research operator with a high level of trust from pharma behemoths. By analyzing the company's profit margins, one can assess the speed of its business model transformation. This indicator captures daily net income, reflecting the business's real-time assessment of market activity. Sharp spikes in the line often signal that the asset is overbought. Investors should cautiously interpret rapid growth to avoid the risk of a corrective drawdown.

Pesaing utama